SEGMENT INFORMATION

6 Months Ended

Sep. 29, 2012

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

Segment Definition Criteria

We manage our business on the basis of one operating segment: the design, manufacture, and marketing of blood management solutions. Our chief operating decision-maker uses consolidated results to make operating and strategic decisions. Manufacturing processes, as well as the regulatory environment in which we operate, are largely the same for all product lines.

Enterprise Wide Disclosures about Product and Services

We have four global product families: plasma, blood center, hospital, and software solutions. Beginning August 1, 2012, we integrated the whole blood business as part of blood center product family.

Our products include manual blood collection kits, devices and the disposable single-use sterile kits used with these devices. Disposables include the plasma, blood center, and hospital product families. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components and subsequent collection of plasma to be used as a raw material for biologically derived pharmaceuticals (also known as source plasma). Blood center consists of manual collection kits and disposables which separate whole blood for the subsequent collection of platelets, plasma, red cells, or a combination of these components for transfusion to patients. Hospital consists of surgical disposables (principally the Cell Saver^® and Cell Saver Elite ^® autologous blood recovery systems targeted to procedures that involve rapid, high volume blood loss such as cardiovascular surgeries and the cardioPAT^® cardiovascular perioperative autotransfusion system designed to remain with the patient following cardiovascular surgery to recover blood and the patient’s red cells to prepare them for reinfusion), the OrthoPAT^® orthopedic perioperative autotransfusion system designed to operate both during and after orthopedic surgery to recover and wash the patient’s red cells to prepare them for reinfusion, and diagnostics products (principally the TEG^® Thrombelastograph^® hemostasis analyzer used to help assess a surgical patient’s blood clotting ability before, during and after surgery).

Software solutions include information technology platforms that assist blood centers, plasma centers, and hospitals to more effectively manage regulatory compliance and operational efficiency.

Revenues from External Customers:

	Three Months Ended
(in thousands)	September 29, 2012		October 1, 2011
Disposable revenues
Plasma disposables	$	68,677	$	64,408
Blood center disposables
Platelet	43,198		42,195
Red cell	11,918		11,645
Whole blood	28,620		—
	83,736		53,840
Hospital disposables
Surgical	18,804		16,206
OrthoPAT	7,645		7,295
Diagnostics	6,937		5,659
	33,386		29,160
Disposables revenue	185,799		147,408
Software solutions	18,043		17,199
Equipment & other	14,336		14,838
Net revenues	$	218,178	$	179,445

	Six Months Ended
(in thousands)	September 29, 2012		October 1, 2011
Disposable revenues
Plasma disposables	$	132,555	$	127,168
Blood center disposables
Platelet	80,440		79,504
Red cell	23,986		23,514
Whole blood	28,620		—
	133,046		103,018
Hospital disposables
Surgical	37,064		31,948
OrthoPAT	15,186		15,049
Diagnostics	13,436		11,273
	65,686		58,270
Disposables revenue	331,287		288,456
Software solutions	35,347		35,359
Equipment & other	28,019		26,199
Net revenues	$	394,653	$	350,014